Biopharmx Corporatio (BPMX) 0.72 $BPMX
BioPharmX to Report First Quarter Financial Results on June 14, 2016
PR Newswire - 2 hrs 7 mins ago
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal first quarter ended April 30, 2016 after the close of trading on Tuesday, June 14, 2016. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PDT/4:30 p.m. EDT.
BPMX: 0.72 (unch)
BioPharmX Presents at American Congress of Obstetricians and Gynecologists (ACOG) Suggesting Molecular Iodine May be Effective, Non-hormonal Treatment for FBC
PR Newswire - Mon May 16, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
BPMX: 0.72 (unch)
BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breasts
PR Newswire Europe - Mon May 09, 6:02AM CDT
Company is one of a handful of presenters featured during the global conference
BPMX: 0.72 (unch)
BioPharmX Corporation Reports Fourth Quarter and Fiscal Year End Financial Results
PR Newswire - Tue Apr 26, 3:10PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the fourth quarter and fiscal year ended January 31, 2016.
BPMX: 0.72 (unch)
BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne
PR Newswire - Mon Apr 25, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01.
BPMX: 0.72 (unch)
BioPharmX to Report Fourth Quarter and Full Year Financial Results on April 26, 2016
PR Newswire - Wed Apr 13, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal fourth quarter and full year ended January 31, 2016 after the close of trading on Tuesday, April 26, 2016. The company's management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
BPMX: 0.72 (unch)
Health Canada Approves BioPharmX Corporation Study of Violet® Iodine
PR Newswire - Mon Apr 04, 7:30AM CDT
BioPharmX engages KGK Synergize, Inc. to manage its Canadian phase 4 study for Violet molecular iodine breast health supplement
BPMX: 0.72 (unch)
BioPharmX Corporation Announces Closing Of $4.3 Million Public Offering
PR Newswire - Fri Apr 01, 10:45AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the closing of its previously announced underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock, with a public offering price of $1.20 per share and related warrant. The warrants have an exercise price of $1.20 per share, are exercisable immediately and expire on April 1, 2021. The transaction included participation from existing investors, including investment vehicles of Franklin Advisers.
BPMX: 0.72 (unch)
BioPharmX Corporation Announces Pricing Of Public Offering To Raise $4.3 Million
PR Newswire - Tue Mar 29, 8:16AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the pricing of an underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock with a public offering price of $1.20 for one share of common stock and a warrant to purchase 0.5 of a share of common stock. The company expects to receive gross proceeds of approximately $4.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The company has also granted the underwriters a 45 day option to purchase up to an additional 324,000 shares of common stock and/or warrants to purchase up to an additional 162,000 shares of common stock to cover over-allotments, if any.
BPMX: 0.72 (unch)
BioPharmX Corporation Announces Proposed Public Offering of Common Stock and Warrants
PR Newswire - Mon Mar 28, 3:05PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
BPMX: 0.72 (unch)
BioPharmX Corporation Initiates Post-Market Phase IV Study for Fibrocystic Breast Condition (FBC) and Cyclic Mastalgia
PR Newswire - Tue Mar 22, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for use in dermatology and women's health, today announced it has received institutional review board (IRB) approval to initiate a Phase 4 study of its Violet® molecular iodine supplement for fibrocystic breast condition (FBC) and cyclic mastalgia.
BPMX: 0.72 (unch)
BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01
PR Newswire - Thu Mar 03, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will immediately commence a Phase 2a clinical study under its U.S. FDA Investigational New Drug (IND) application for BPX-01, a hydrophilic formulation of the well-established drug minocycline. This clinical study will assess effectiveness in reducing the number of acne-causing bacteria in study patients at four weeks and evaluate the drug's safety and tolerability. This is the first clinical study in the clinical development program for BPX-01.
BPMX: 0.72 (unch)
BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directors
PR Newswire - Wed Jan 27, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that Craig A. Barbarosh has joined the company's board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee.
BPMX: 0.72 (unch)
BioPharmX's BPX-01 topical formulation may offer breakthrough in acne treatment
M2 - Mon Jan 18, 5:24AM CST
Pharmaceutical company BioPharmX (NYSE MKT: BPMX) said on Friday that its research shows that its unique formulation of minocycline, called BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.72 (unch)
Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
PR Newswire - Fri Jan 15, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at the 2016 Winter Clinical Dermatology Conference next week shows its unique formulation of minocycline, known as BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.72 (unch)
BioPharmX Violet Iodine Mobile Marketing Campaign On Pandora Achieves 25 Times the Average Industry Response
PR Newswire - Tue Jan 12, 7:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX) today announced that its preliminary campaign test results of advertising on Pandora (NYSE: P), the world's most powerful music discovery platform, show that personalized, streaming radio is an innovative, effective way to drive consumer awareness of Violet® iodine, a new breast health supplement for women.
P: 12.07 (-0.10), BPMX: 0.72 (unch)
Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.80 (-0.01), XRM: 7.09 (+0.04), TBBK: 6.85 (unch), BPMX: 0.72 (unch)
BioPharmX Corporation Reports Third Quarter Financial Results
PR Newswire - Mon Dec 14, 3:05PM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the third fiscal quarter ended October 31, 2015.
BPMX: 0.72 (unch)
BioPharmX to Report First Quarter Financial Results on June 14, 2016
PR Newswire - 2 hrs 7 mins ago
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal first quarter ended April 30, 2016 after the close of trading on Tuesday, June 14, 2016. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PDT/4:30 p.m. EDT.
BPMX: 0.72 (unch)
BioPharmX Presents at American Congress of Obstetricians and Gynecologists (ACOG) Suggesting Molecular Iodine May be Effective, Non-hormonal Treatment for FBC
PR Newswire - Mon May 16, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, addressed a major ob-gyn meeting this weekend and encouraged the assessment of molecular iodine as a non-hormonal treatment for pain associated with fibrocystic breast condition (FBC) and a viable alternative to the current standard of care.
BPMX: 0.72 (unch)
BioPharmX to Present Research at Vitafoods Europe Showing that Molecular Iodine is Key to the Healthy Aging of Women's Breasts
PR Newswire Europe - Mon May 09, 6:02AM CDT
Company is one of a handful of presenters featured during the global conference
BPMX: 0.72 (unch)
BioPharmX Corporation Reports Fourth Quarter and Fiscal Year End Financial Results
PR Newswire - Tue Apr 26, 3:10PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the fourth quarter and fiscal year ended January 31, 2016.
BPMX: 0.72 (unch)
BioPharmX Announces Full Patient Enrollment in Phase 2a Study of BPX-01 Topical Antibiotic for Acne
PR Newswire - Mon Apr 25, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01.
BPMX: 0.72 (unch)
BioPharmX to Report Fourth Quarter and Full Year Financial Results on April 26, 2016
PR Newswire - Wed Apr 13, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will release its financial results for the fiscal fourth quarter and full year ended January 31, 2016 after the close of trading on Tuesday, April 26, 2016. The company's management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments.
BPMX: 0.72 (unch)
Health Canada Approves BioPharmX Corporation Study of Violet® Iodine
PR Newswire - Mon Apr 04, 7:30AM CDT
BioPharmX engages KGK Synergize, Inc. to manage its Canadian phase 4 study for Violet molecular iodine breast health supplement
BPMX: 0.72 (unch)
BioPharmX Corporation Announces Closing Of $4.3 Million Public Offering
PR Newswire - Fri Apr 01, 10:45AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the closing of its previously announced underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock, with a public offering price of $1.20 per share and related warrant. The warrants have an exercise price of $1.20 per share, are exercisable immediately and expire on April 1, 2021. The transaction included participation from existing investors, including investment vehicles of Franklin Advisers.
BPMX: 0.72 (unch)
BioPharmX Corporation Announces Pricing Of Public Offering To Raise $4.3 Million
PR Newswire - Tue Mar 29, 8:16AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced the pricing of an underwritten public offering of 3,600,000 shares of common stock and warrants to purchase 1,800,000 shares of common stock with a public offering price of $1.20 for one share of common stock and a warrant to purchase 0.5 of a share of common stock. The company expects to receive gross proceeds of approximately $4.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The company has also granted the underwriters a 45 day option to purchase up to an additional 324,000 shares of common stock and/or warrants to purchase up to an additional 162,000 shares of common stock to cover over-allotments, if any.
BPMX: 0.72 (unch)
BioPharmX Corporation Announces Proposed Public Offering of Common Stock and Warrants
PR Newswire - Mon Mar 28, 3:05PM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it intends to offer and sell common stock and warrants, subject to market and other conditions, in an underwritten public offering. The common stock and warrants are being offered under the company's effective shelf registration statement previously filed with the Securities and Exchange Commission (SEC). BioPharmX intends to use the net proceeds of the offering for general corporate purposes, which may include funding research and development, increasing working capital, and acquisitions or investments in businesses, products, or technologies that are complementary to its own.
BPMX: 0.72 (unch)
BioPharmX Corporation Initiates Post-Market Phase IV Study for Fibrocystic Breast Condition (FBC) and Cyclic Mastalgia
PR Newswire - Tue Mar 22, 7:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for use in dermatology and women's health, today announced it has received institutional review board (IRB) approval to initiate a Phase 4 study of its Violet® molecular iodine supplement for fibrocystic breast condition (FBC) and cyclic mastalgia.
BPMX: 0.72 (unch)
BioPharmX commences Phase 2 clinical study under U.S. FDA IND for BPX-01
PR Newswire - Thu Mar 03, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that it will immediately commence a Phase 2a clinical study under its U.S. FDA Investigational New Drug (IND) application for BPX-01, a hydrophilic formulation of the well-established drug minocycline. This clinical study will assess effectiveness in reducing the number of acne-causing bacteria in study patients at four weeks and evaluate the drug's safety and tolerability. This is the first clinical study in the clinical development program for BPX-01.
BPMX: 0.72 (unch)
BioPharmX Corporation Appoints Craig A. Barbarosh to its Board of Directors
PR Newswire - Wed Jan 27, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced that Craig A. Barbarosh has joined the company's board of directors. He will serve as an independent board member on the audit and compensation committees and will chair the nominating and corporate governance committee.
BPMX: 0.72 (unch)
BioPharmX's BPX-01 topical formulation may offer breakthrough in acne treatment
M2 - Mon Jan 18, 5:24AM CST
Pharmaceutical company BioPharmX (NYSE MKT: BPMX) said on Friday that its research shows that its unique formulation of minocycline, called BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.72 (unch)
Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
PR Newswire - Fri Jan 15, 8:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company, announced today that research being presented at the 2016 Winter Clinical Dermatology Conference next week shows its unique formulation of minocycline, known as BPX-01, may offer a breakthrough in acne treatment because it may not result in systemic toxicities commonly associated with current use of the orally administered antibiotic.
BPMX: 0.72 (unch)
BioPharmX Violet Iodine Mobile Marketing Campaign On Pandora Achieves 25 Times the Average Industry Response
PR Newswire - Tue Jan 12, 7:00AM CST
BioPharmX Corporation (NYSE MKT: BPMX) today announced that its preliminary campaign test results of advertising on Pandora (NYSE: P), the world's most powerful music discovery platform, show that personalized, streaming radio is an innovative, effective way to drive consumer awareness of Violet® iodine, a new breast health supplement for women.
P: 12.07 (-0.10), BPMX: 0.72 (unch)
Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.80 (-0.01), XRM: 7.09 (+0.04), TBBK: 6.85 (unch), BPMX: 0.72 (unch)
BioPharmX Corporation Reports Third Quarter Financial Results
PR Newswire - Mon Dec 14, 3:05PM CST
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, today announced its financial results for the third fiscal quarter ended October 31, 2015.
BPMX: 0.72 (unch)
